

ZHENG, Jianhao 郑建浩



Tel: (+85 2) 6919 5081

E-mail: zhengjianhao@haiwen-law.com

City: Beijing, Hong Kong

Practices: U.S. and Hong Kong Capital Markets, U.S. and Hong Kong Corporate Compliance

Basic Information

Mr. Zheng is a partner at Haiwen & Partners Hong Kong office. Mr. Zheng specializes in the field of capital markets (U.S. and Hong Kong listings), having long represented issuers and investment banks in Main Board listings on the Hong Kong Stock Exchange and U.S. exchanges. His clients span multiple sectors, including life sciences, technology, media and telecommunications, financial services, and consumer goods. He also has extensive experience in compliance and cross-border matters for listed companies, and possesses a comprehensive understanding of both Hong Kong and U.S. regulatory frameworks.

Professional History

Mr. Zheng joined Haiwen in 2025 as an international partner. Previously, he worked as counsel at Slaughter and May's Hong Kong Office, as well as at several other international law firms' New York and Hong Kong offices.

Experience Highlights

In the area of Hong Kong ECM, Mr. Zheng has acted as the international counsel in several landmark Hong Kong IPO projects, including SenseTime Group's listing in 2021 (China Business Law Review Deals of the Year 2022), Cirrus Aircraft's listing in 2024 (the second-largest Hong Kong IPO that year), and Zijin Gold International Company Limited's listing in 2025 (one of the largest Hong Kong IPOs that year).

Projects where Mr. Zheng acted as the international counsel for either the issuer or the underwriters also include: Sunshine Lake Pharma Co., Ltd., Yidu Technology, Stealth BioTherapeutics Corp., Suzhou Kintor Pharmaceuticals, AOBiome LLC, Zhubaijie Network, Cirrus Aircraft, FWD Group, China Reinsurance (Group) Corporation, YiChang HEC ChangJiang Pharmaceutical Co., Ltd., Union Medical Healthcare Limited, Dekon Food and Agriculture, China Hengshi Foundation Company Limited, V3 Group Limited, Australia's largest coal producer - Yancoal Australia, Macau Legend Development Limited, Times Property Holdings Limited, Lingyi iTech, and Dongwei Technology.

In the area of U.S. capital markets, Mr. Zheng has rich experience in prospectus drafting and SEC filings, including quarterly and annual reports, information statements, Form 13-D disclosures, and Form 8-K filings.

Admissions

Mr. Zheng is licensed to practice law in New York State and Hong Kong.

Education

Mr. Zheng holds a Bachelor of Science degree in Biology from Peking University and a J.D. degree from Fordham

University School of Law in the United States. He also pursued doctoral studies in the Department of Biology at the University of Pennsylvania.

Language

Mandarin, English